While the exclusive and transformative pipelines of OncoDxRx’s deep dive into precision diagnostics capabilities are largely recognizable, the company said the one-of-a-kind capabilities will shape future milestones and architecture decisions.

The pipelines are part of a broader OncoDxRx’s effort to capitalize key technologies that affect precision oncology across multiple mission areas — and it follows a push from the company in recent years to better leverage the functional genomics-informed decision-making for cancer early detection, treatment selection, therapeutic response monitoring, and recurrence prediction.

While there is a widespread understanding of the significant impact of personalized medicine via biomarker testing, OncoDxRx said the non-responder population has traditionally been excluded, with targeted therapy-matched responders almost always taking priority.

“Our own experience suggests that this is a historically neglected area that can have an oversized impact but doesn’t compete well in current pharmaceutical and clinical settings relative to other priorities,” the company said in a keynote speech.

OncoDxRx didn’t discuss their findings in detail but noted that the company is particularly interested in the role of blood-based gene expression technologies in informing treatment selection (eg., the PGA test - Patient-derived Gene expression-informed Anticancer drug efficacy) and monitoring residual disease (eg., the OncoMRD assay) for solid tumors.

“We believe we can counter advanced cancer kill webs in the patient non-responders by integrating a combination of liquid biopsy diagnostics tools, operationalized in vitro and in silico analytics and other elements,” OncoDxRx said. “We’re excited to see us making fast progress on these mission areas.”

The company is already in the process of launching an open architecture for therapeutic decision and response monitoring capabilities and has been working to increase the speed at which it can update these systems with real-time real-world data.

“We have to be able to continue to add pressure in a war against cancer in order to seize the advantage and keep our promise for precision medicine to be accessible to every patient,” OncoDxRx said. “To benefit the non-responder population is the final piece of puzzle that will allow this to happen, and PGA and OncoMRD are the ways to do that.”